These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 24898058)

  • 81. Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation.
    Gibson BA; Zhang Y; Jiang H; Hussey KM; Shrimp JH; Lin H; Schwede F; Yu Y; Kraus WL
    Science; 2016 Jul; 353(6294):45-50. PubMed ID: 27256882
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Characterization of DNA ADP-ribosyltransferase activities of PARP2 and PARP3: new insights into DNA ADP-ribosylation.
    Zarkovic G; Belousova EA; Talhaoui I; Saint-Pierre C; Kutuzov MM; Matkarimov BT; Biard D; Gasparutto D; Lavrik OI; Ishchenko AA
    Nucleic Acids Res; 2018 Mar; 46(5):2417-2431. PubMed ID: 29361132
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cell Cycle Resolved Measurements of Poly(ADP-Ribose) Formation and DNA Damage Signaling by Quantitative Image-Based Cytometry.
    Michelena J; Altmeyer M
    Methods Mol Biol; 2017; 1608():57-68. PubMed ID: 28695503
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
    Makogon NV; Aleksieieva IM
    Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Poly-ADP-ribose polymerase: machinery for nuclear processes.
    Thomas C; Tulin AV
    Mol Aspects Med; 2013 Dec; 34(6):1124-37. PubMed ID: 23624145
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Tankyrase-1 overexpression reduces genotoxin-induced cell death by inhibiting PARP1.
    Yeh TY; Sbodio JI; Nguyen MT; Meyer TN; Lee RM; Chi NW
    Mol Cell Biochem; 2005 Aug; 276(1-2):183-92. PubMed ID: 16132700
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.
    Lehtiö L; Jemth AS; Collins R; Loseva O; Johansson A; Markova N; Hammarström M; Flores A; Holmberg-Schiavone L; Weigelt J; Helleday T; Schüler H; Karlberg T
    J Med Chem; 2009 May; 52(9):3108-11. PubMed ID: 19354255
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A new facet of ADP-ribosylation reactions: SIRTs and PARPs interplay.
    Faraone-Mennella MR
    Front Biosci (Landmark Ed); 2015 Jan; 20(3):458-73. PubMed ID: 25553461
    [TBL] [Abstract][Full Text] [Related]  

  • 91. PARPs and the DNA damage response.
    Sousa FG; Matuo R; Soares DG; Escargueil AE; Henriques JA; Larsen AK; Saffi J
    Carcinogenesis; 2012 Aug; 33(8):1433-40. PubMed ID: 22431722
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Equilibrium model in an in vitro poly(ADP-ribose) turnover system.
    Lagueux J; Ménard L; Candas B; Brochu G; Potvin F; Verreault A; Cook PF; Poirier GG
    Biochim Biophys Acta; 1995 Nov; 1264(2):201-8. PubMed ID: 7495864
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Analysis of ADP-ribose polymer sizes in intact cells.
    Gagné JP; Shah RG; Poirier GG
    Mol Cell Biochem; 2001 Aug; 224(1-2):183-5. PubMed ID: 11693195
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice.
    Cozzi A; Cipriani G; Fossati S; Faraco G; Formentini L; Min W; Cortes U; Wang ZQ; Moroni F; Chiarugi A
    J Cereb Blood Flow Metab; 2006 May; 26(5):684-95. PubMed ID: 16177811
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes.
    Wigle TJ; Church WD; Majer CR; Swinger KK; Aybar D; Schenkel LB; Vasbinder MM; Brendes A; Beck C; Prahm M; Wegener D; Chang P; Kuntz KW
    SLAS Discov; 2020 Mar; 25(3):241-252. PubMed ID: 31855104
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Large-scale preparation and characterization of poly(ADP-ribose) and defined length polymers.
    Tan ES; Krukenberg KA; Mitchison TJ
    Anal Biochem; 2012 Sep; 428(2):126-36. PubMed ID: 22743307
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Activation of the SNF2 family ATPase ALC1 by poly(ADP-ribose) in a stable ALC1·PARP1·nucleosome intermediate.
    Gottschalk AJ; Trivedi RD; Conaway JW; Conaway RC
    J Biol Chem; 2012 Dec; 287(52):43527-32. PubMed ID: 23132853
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Mechanisms governing PARP expression, localization, and activity in cells.
    Sanderson DJ; Cohen MS
    Crit Rev Biochem Mol Biol; 2020 Dec; 55(6):541-554. PubMed ID: 32962438
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Catching mono- and poly-ADP-ribose readers with synthetic ADP-ribose baits.
    Cohen MS
    Mol Cell; 2021 Nov; 81(21):4351-4353. PubMed ID: 34739826
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
    Kwon M; Jang H; Kim EH; Roh JL
    Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.